Ocugen, Inc. (OCGN)
1.36
+0.01
(+0.74%)
USD |
NASDAQ |
Sep 04, 16:00
1.36
0.00 (0.00%)
After-Hours: 20:00
Ocugen SG&A Expense (TTM) : 29.72M for June 30, 2026
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 29.72M |
| March 31, 2026 | 29.24M |
| December 31, 2025 | 27.58M |
| September 30, 2025 | 27.76M |
| June 30, 2025 | 25.81M |
| March 31, 2025 | 26.74M |
| December 31, 2024 | 26.69M |
| September 30, 2024 | 25.53M |
| June 30, 2024 | 28.33M |
| March 31, 2024 | 30.09M |
| December 31, 2023 | 31.99M |
| September 30, 2023 | 33.85M |
| June 30, 2023 | 32.26M |
| March 31, 2023 | 33.37M |
| December 31, 2022 | 35.18M |
| September 30, 2022 | 35.64M |
| June 30, 2022 | 32.66M |
| March 31, 2022 | 28.85M |
| December 31, 2021 | 22.92M |
| September 30, 2021 | 17.66M |
| June 30, 2021 | 14.86M |
| March 31, 2021 | 9.882M |
| December 31, 2020 | 7.974M |
| September 30, 2020 | 8.293M |
| June 30, 2020 | 7.996M |
| Date | Value |
|---|---|
| March 31, 2020 | 7.306M |
| December 31, 2019 | 6.077M |
| September 30, 2019 | 6.318M |
| June 30, 2019 | 5.753M |
| March 31, 2019 | 7.491M |
| December 31, 2018 | 9.250M |
| September 30, 2018 | 9.143M |
| June 30, 2018 | 10.52M |
| March 31, 2018 | 9.865M |
| December 31, 2017 | 9.384M |
| September 30, 2017 | 9.106M |
| June 30, 2017 | 8.649M |
| March 31, 2017 | 8.644M |
| December 31, 2016 | 8.53M |
| September 30, 2016 | 8.372M |
| June 30, 2016 | 8.795M |
| March 31, 2016 | 8.369M |
| December 31, 2015 | 8.266M |
| September 30, 2015 | 7.938M |
| June 30, 2015 | 7.45M |
| March 31, 2015 | 7.029M |
| December 31, 2014 | 6.746M |
| September 30, 2014 | 6.76M |
| June 30, 2014 | 5.807M |
| March 31, 2014 | 5.768M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 620.29M |
| Anika Therapeutics, Inc. | 52.67M |
| Gilead Sciences, Inc. | 9.147B |
| MannKind Corp. | 341.36M |
| Vertex Pharmaceuticals, Inc. | 2.008B |